This article is more than 5 years old. Information may no longer be current.
Lux Biosciences granted FDA priority review for oral voclosporin
Click Here to Manage Email Alerts
JERSEY CITY, N.J. — The U.S. Food and Drug Administration has accepted Lux Biosciences' new drug application for oral voclosporin and has granted the application priority review, Lux Biosciences announced in a press release.
The drug, called Luveniq (voclosporin), is a next-generation calcineurin inhibitor that reversibly inhibits immunocompetent lymphocytes, as well as the production and release of lymphokine, the release said.
"We are very pleased that Luveniq is now under active regulatory consideration in both the United States and Europe, and that the FDA is providing an expedited review in recognition of the potential of this experimental drug and high need for new therapies," Eddy Anglade, MD, chief medical officer for Lux Biosciences, said in the release.
Lux Biosciences owns exclusive worldwide rights to voclosporin for all ophthalmic indications.
Follow OSNSuperSite.com
on Twitter.